3SBio Inc. TRSBF

Company Overview

3SBio Inc. is a China-based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic medicines and specialty pharmaceuticals. The company operates primarily in the biotechnology and pharmaceutical industries, with a concentration on oncology, nephrology, autoimmune diseases, dermatology, and metabolic disorders. Listed on the Hong Kong Stock Exchange under the ticker 1530.HK and traded in the U.S. over-the-counter market as TRSBF, 3SBio has established itself as one of the larger domestic biotechnology companies in China with integrated development and manufacturing capabilities.

The company’s primary revenue drivers include marketed biologic therapies such as recombinant human thrombopoietin products, erythropoietin products, and oncology-related therapeutics. Key products include TPIAO, Yisaipu, Cipterbin, and Mandi. 3SBio serves hospitals, physicians, and healthcare systems across China while also expanding selected products internationally through licensing and commercialization partnerships. The company traces its origins to the early 1990s and evolved from a domestic biologics producer into a diversified biotechnology enterprise through internal R&D expansion, acquisitions, and strategic licensing arrangements.

Business Operations

3SBio organizes its operations around pharmaceutical research, manufacturing, commercialization, and licensing activities. Its principal operating businesses include biologics manufacturing, innovative drug development, and commercial pharmaceutical sales. Major business and product platforms include TPIAO for thrombocytopenia treatment, Yisaipu for autoimmune diseases, and oncology-focused therapies distributed through the company’s specialty pharmaceutical infrastructure. Revenue is primarily generated from product sales in mainland China, supplemented by licensing income and collaboration agreements.

The company maintains domestic manufacturing facilities compliant with Chinese and international pharmaceutical standards and operates a vertically integrated platform spanning clinical development through commercialization. Subsidiaries and affiliated entities include Shenyang Sunshine Pharmaceutical Co., Ltd., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., and Sirton Pharmaceuticals S.p.A. in Italy. 3SBio has also entered partnerships with biotechnology firms and multinational pharmaceutical companies to co-develop and commercialize therapies in oncology and immunology. International operations remain smaller than its China business but include manufacturing, licensing, and collaborative development activities across Asia and Europe.

Strategic Position & Investments

3SBio’s strategic direction centers on expanding its innovative biologics portfolio, strengthening oncology capabilities, and advancing next-generation therapies through internal development and external partnerships. The company has invested heavily in monoclonal antibodies, biosimilars, nephrology products, and immuno-oncology assets. Research efforts have included antibody-drug conjugates, recombinant proteins, and cell therapy-related technologies. Management has emphasized increasing the proportion of revenue derived from innovative medicines versus mature pharmaceutical products.

The company has pursued growth through acquisitions and equity investments, including the acquisition of Sirton Pharmaceuticals S.p.A., which expanded manufacturing and European production capabilities. 3SBio has also maintained strategic investments and collaborations involving oncology drug candidates and biologics platforms. Its pipeline includes products targeting cancer, inflammatory diseases, and hematologic conditions, positioning the company within segments prioritized by China’s healthcare and biotechnology development policies. Public disclosures indicate continued investment in clinical trials, manufacturing expansion, and commercialization infrastructure.

Geographic Footprint

3SBio is headquartered in Shenyang, Liaoning Province, China, with major operational and research activities distributed across several Chinese cities, including Shanghai, Shenzhen, and other pharmaceutical manufacturing hubs. China remains the company’s dominant market and the primary source of revenue, supported by nationwide hospital distribution and sales networks serving large public healthcare systems.

Outside China, the company maintains a more limited but growing international footprint through subsidiaries, licensing arrangements, and manufacturing assets. Its ownership of Sirton Pharmaceuticals S.p.A. provides an operational base in Italy and broader access to European pharmaceutical manufacturing capabilities. 3SBio has also pursued selective commercial and research collaborations in Asia, Europe, and other international markets, although the majority of commercial activity remains concentrated within mainland China.

Leadership & Governance

3SBio was founded by entrepreneur and investor Lou Jing, who played a major role in the company’s early development and expansion into biologics. Corporate governance is overseen by a board of directors and executive management team focused on innovation-driven pharmaceutical growth, commercialization efficiency, and expansion of the company’s biologics pipeline. Public filings and investor materials emphasize long-term investment in R&D, operational integration, and scaling innovative therapies within China’s healthcare market.

Key executives include:

• Lou Jing – Chairman of the Board
• Ma Jilin – Chief Executive Officer
• Zhou Xuesong – Executive Director
• Liu Dongying – Senior Vice President
• Liang Xiaofeng – Chief Financial Officer

The company’s leadership strategy has consistently emphasized biologics innovation, domestic market leadership in specialty therapeutics, and international collaboration to strengthen manufacturing, research, and commercialization capabilities.